Source comparison
Best Ipamorelin Dosage Growth Hormone Release 2026: Comparison Analysis
100–150mcg single dose 6–8× 90–120 minutes Minimal Preliminary dose-response studies Subtherapeutic for most GH secretion research. Useful for initial tolerance testing only 200–300mcg 2–3× daily 13–15× 120–180 minutes Low (with 3hr spacing) Standard monothera
This comparison does not assign a generated winner or score.
- 100–150mcg single dose
- 6–8×
- 90–120 minutes
- Minimal
- Preliminary dose-response studies
- Subtherapeutic for most GH secretion research. Useful for initial tolerance testing only
- 200–300mcg 2–3× daily
- 13–15×
- 120–180 minutes
- Low (with 3hr spacing)
- Standard monotherapy GH pulse research
- Gold standard for ipamorelin research in 2026. Optimal balance of GH response and receptor preservation
- 200–300mcg + CJC-1295 100mcg
- 20–25×
- 180–240 minutes
- Moderate (requires 4–6hr spacing)
- Synergistic dual-agonist protocols
- Maximizes GH output when extended pulse duration is required. Most common in body composition studies
- 500mcg+ single dose
- 14–16× (minimal increase vs 300mcg)
- High. Receptor desensitization
- Not recommended in current research
- Wastes compound without proportional GH benefit. Excess peptide circulates unbound
- Continuous low-dose infusion
- 3–5× sustained
- Continuous
- Severe. Chronic downregulation
- Obsolete. Replaced by pulsed protocols
- Destroys physiological GH pulse architecture and causes receptor internalization within 48–72 hours